Revenue: As of FY2025 Q1, the actual value is USD 2.806 M.EPS: As of FY2025 Q1, the actual value is USD -0.09.EBIT: As of FY2025 Q1, the actual value is USD -678 K.<h3>Segment Revenue</h3><ul><li>NexGel Segment: Total revenue for the quarter ended March 31, 2025 was $1,998 thousand, compared to $850 thousand for the same period in 2024.</li><li>CGN JV Segment: Total revenue for the quarter ended March 31, 2025 was $808 thousand, compared to $416 thousand for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>NexGel Segment: Loss from operations for the quarter ended March 31, 2025 was - $872 thousand, compared to - $779 thousand for the same period in 2024.</li><li>CGN JV Segment: Income from operations for the quarter ended March 31, 2025 was $95 thousand, compared to a loss of - $92 thousand for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the three months ended March 31, 2025, net cash used in operating activities was - $400 thousand, compared to - $1,092 thousand for the same period in 2024.</li><li>Net Cash Used in Investing Activities: For the three months ended March 31, 2025, net cash used in investing activities was $0, compared to - $118 thousand for the same period in 2024.</li><li>Net Cash Used in Financing Activities: For the three months ended March 31, 2025, net cash used in financing activities was - $215 thousand, compared to $929 thousand for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Deferred Revenue: As of March 31, 2025, deferred revenue was $286 thousand, compared to $179 thousand as of December 31, 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: NexGel plans to maintain and grow its existing contract manufacturing business and continue developing its catalogue of consumer products for sale to branding partners. The company aims to develop proprietary medical devices and explore drug delivery programs for its technology.</li><li>Non-Core Business: The company continues to evaluate strategic initiatives, such as acquisitions, and additional capital raises through debt or equity may be necessary to achieve these objectives.</li></ul>

NEXGEL INC C/WTS 27/12/2026 (TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 2.806 M